Clinical trial
A Phase 1/2, Two-Arm, Dose-Finding Study of Natalizumab for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
NCT00675428 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Two-Arm, Dose-Finding Study of Natalizumab for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Biogen
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 30, 2008
- Completion date
- December 31, 2009
- Enrollment
- 6 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.